

**CORRECTION**


# Correction: The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials

Qi-Hong Chen<sup>1</sup>, Yi Yang<sup>1</sup>, Hong-Li He<sup>1</sup>, Jian-Feng Xie<sup>1</sup>, Shi-Xia Cai<sup>1</sup>, Ai-Ran Liu<sup>1</sup>, Hua-Ling Wang<sup>2</sup> and Hai-Bo Qiu<sup>1\*</sup>

See related research by Chen et al., <http://ccforum.com/content/18/1/R8>

After publication of our article in a recent issue of *Critical Care* [1], inconsistencies were identified in Figure 6. Four trials - by Fuentes-Orozco and colleagues [2,3], Hall and colleagues [4], and Goeters and colleagues [5] - were allocated to

the wrong subgroup in our meta-analysis. They should have been included in the first subgroup (glutamine <0.3 g/kg per day); this does not change the significance of the results ( $P = 0.01$ ). The correct Figure 6 is given here in full as Figure 1.



\* Correspondence: [haiboq2000@gmail.com](mailto:haiboq2000@gmail.com)

<sup>1</sup>Department of Critical Care Medicine, Zhong-Da Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, P.R. China  
Full list of author information is available at the end of the article

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Critical Care Medicine, Zhong-Da Hospital, School of Medicine, Southeast University, 87 Dingjiaqiao Road, Nanjing 210009, P.R. China.

<sup>2</sup>Department of Critical Care Medicine, Su-Bei Hospital of Jiangsu Provience & Clinical Medical School, Yangzhou University, Yangzhou, Jiangsu, P.R. China.

Published: 17 June 2014

### References

1. Chen QH, Yang Y, He HL, Xie JF, Cai SX, Liu AR, Wang HL, Qiu HB: The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials. *Crit Care* 2014, **18**:R8.
2. Fuentes-Orozco C, Anaya-Prado R, González-Ojeda A, Arenas-Márquez H, Cabrera-Pivalar C, Cervantes-Guevara G, Barrera-Zepeda LM: L-alanyl-L-glutamine-supplemented parenteral nutrition improves infectious morbidity in secondary peritonitis. *Clin Nutr* 2004, **23**:13–21.
3. Fuentes-Orozco C, Cervantes-Guevara G, Muciño-Hernández I, López-Ortega A, Ambriz-González G, Gutiérrez-de-la-Rosa JL, Gómez-Herrera E, Hermosillo-Sandoval JM, González-Ojeda A: L-alanyl-L-glutamine-supplemented parenteral nutrition decreases infectious morbidity rate in patients with severe acute pancreatitis. *JPEN J Parenter Enteral Nutr* 2008, **32**:403–411.
4. Hall JC, Dobb G, Hall J, de Sousa R, Brennan L, McCauley R: A prospective randomized trial of enteral glutamine in critical illness. *Intensive Care Med* 2003, **29**:1710–1716.
5. Goeters C, Wenn A, Mertes N, Wempe C, Van Aken H, Stehle P, Bone HG: Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients. *Crit Care Med* 2002, **30**:2032–2037.

doi:10.1186/cc13926

**Cite this article as:** Chen et al.: Correction: The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials. *Critical Care* 2014 **18**:436.